Original language | English (US) |
---|---|
Pages (from-to) | 3251-3258 |
Number of pages | 8 |
Journal | European heart journal |
Volume | 34 |
Issue number | 42 |
DOIs |
|
State | Published - Nov 7 2013 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Stabilization of atherosclerotic plaques : An update. / Ylä-Herttuala, Seppo; Bentzon, Jacob Fog; Daemen, Mat; Falk, Erling; Garcia-Garcia, Hector M.; Herrmann, Joerg; Hoefer, Imo; Jauhiainen, Suvi; Jukema, J. Wouter; Krams, Rob; Kwak, Brenda R.; Marx, Nikolaus; Naruszewicz, Marek; Newby, Andrew; Pasterkamp, Gerard; Serruys, Patrick W.J.C.; Waltenberger, Johannes; Weber, Christian; Tokgözoglu, Lale.
In: European heart journal, Vol. 34, No. 42, 07.11.2013, p. 3251-3258.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Stabilization of atherosclerotic plaques
T2 - An update
AU - Ylä-Herttuala, Seppo
AU - Bentzon, Jacob Fog
AU - Daemen, Mat
AU - Falk, Erling
AU - Garcia-Garcia, Hector M.
AU - Herrmann, Joerg
AU - Hoefer, Imo
AU - Jauhiainen, Suvi
AU - Jukema, J. Wouter
AU - Krams, Rob
AU - Kwak, Brenda R.
AU - Marx, Nikolaus
AU - Naruszewicz, Marek
AU - Newby, Andrew
AU - Pasterkamp, Gerard
AU - Serruys, Patrick W.J.C.
AU - Waltenberger, Johannes
AU - Weber, Christian
AU - Tokgözoglu, Lale
N1 - Funding Information: Conflict of interest: I.H. has received research grants from NWO, CTMM, BMM, and TI Pharma. J.W.J. has received grants from Astellas, Astra-Zeneca, Biotronik, Boston Scientific, Daiichi Sankyo, Lilly, Genzyme, Medtronic, MSD, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi-Aventis, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands, and the European Community Framework FP7 Programme. R.K. has received grants from the Netherlands and British Heart Foundations, the CTMM, the BBSRC and EPSRC, the FP7 Programme, and Johnson & Johnson. B.R.K. has received grants from the Swiss National Science Foundation, Fondation Leenaards, and the Fondation Prevot. N.M. has received research grants from Boehringer Ingelheim, GSK, MSD, and Takeda. A.N. has received grants from the British Heart Foundation and the UK National Institute for Health Research. He is also consultant for PlaqueTec. G.P. is a co-founder of Cavadis. C.W. is a shareholder of Carolus Therapeutics, Inc. S.Y.-H has received grants from the Academy of Finland, the Finnish Heart Foundation, and EU FP7 programme grants CliniGene, Baculogenes, BIOMAGSCAR, and BAMI. Funding Information: This study was supported by ESC Working Group of Atherosclerosis and Vascular Biology.
PY - 2013/11/7
Y1 - 2013/11/7
UR - http://www.scopus.com/inward/record.url?scp=84890473570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890473570&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/eht301
DO - 10.1093/eurheartj/eht301
M3 - Comment/debate
C2 - 23966311
AN - SCOPUS:84890473570
VL - 34
SP - 3251
EP - 3258
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 42
ER -